patent/WO-2005035570-A3

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fac65659bfec1cdbccaa51b16b8b1d59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_149d55cea8fd237cb35f3ab63cda9b7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ecb6b815d60a933d2e5dddc643f72d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae70aed5690f31c080d54cd4813aeeb
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
filingDate	2004-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8149130cd7595bb88163bd6a6383308a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dde34eee2e029e31e7db7235d1e789d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e886da0fcbf97c4806c67bc6c06d5094
publicationDate	2005-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	WO-2005035570-A3
titleOfInvention	Variants of cd40l protein
abstract	The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in E. coli. The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same.
priorityDate	2003-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02087627-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0218445-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9640918-A2
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4640 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394213

Total number of triples: 21.